Adaptive Biotechnologies Corp Dossier
Qualitative Analysis
Business overview
Adaptive Biotechnologies Corp (NASDAQ: ADPT) is a commercial-stage biotechnology company advancing the field of immune-driven medicine. The company leverages its proprietary immune medicine platform to read and translate the massive genetic diversity of the adaptive immune system. Its core commercial product is clonoSEQ, a next-generation sequencing (NGS) test used to detect and monitor minimal residual disease (MRD) in patients with hematologic malignancies such as multiple myeloma, leukemia, and lymphoma. In June 2026, the company announced a major strategic pivot to separate its highly profitable MRD business from its AI-powered Immune Medicine business, aiming to unlock shareholder value by allowing each segment to pursue tailored growth strategies.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pursuing a separation of the Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is actively evaluating strategic and structural alternatives for the Immune Medicine segment—including potential sale, spin-off, partnership, or licensing transactions—to support its growth and capital needs outside of Adaptive's diagnostic commercial model.
Expected impact: Allows the profitable MRD business to focus on diagnostics leadership while unlocking the value of the Immune Medicine segment's AI-driven discovery platform and massive TCR-antigen dataset.
Expanding the clinical utility and adoption of the clonoSEQ MRD platform. Key operational goals include increasing blood-based testing to over 50% of clonoSEQ tests, expanding community oncology presence to over 35% of testing, integrating approximately 40 additional accounts with Electronic Medical Record (EMR) systems, and increasing registrational studies in multiple myeloma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma.
Expected impact: Drives clonoSEQ volume and revenue growth, supporting the raised full year 2026 MRD revenue guidance of $260 million to $270 million, representing annual growth of 22% to 27%.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Validates the commercial and scientific value of Adaptive's TCR-antigen library and AI-driven discovery platform. The first agreement focuses on identifying disease-causing TCRs as potential therapeutic targets in rheumatoid arthritis, while the second multi-year agreement grants Pfizer access to Adaptive's TCR-antigen datasets to train AI/ML prediction models.
Terms: Includes upfront payments and potential future annual licensing fees, with total milestone payments potentially worth up to $890 million.